The FDA has approved a treatment for Friedreich ataxia after the results of randomized, placebo-controlled study indicate a strong effectiveness in treatment.
In a new study, researchers used the largest aggregate of genome-wide association studies data to identify novel risk loci and gained further insight into the causes of Parkinson disease.
